Mechanisms that underlie μ-opioid receptor agonist-induced constipation: Differential involvement of μ-opioid receptor sites and responsible regions

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 1, 2013, Pages 91-99

  Mori, Tomohisa ^a   Shibasaki, Yumiko ^a   Matsumoto, Kenjiro ^a,b   Shibasaki, Masahiro ^a   Hasegawa, Minami ^a   Wang, Erika ^a   Masukawa, Daiki ^a   Yoshizawa, Kazumi ^a,c   Horie, Syunji ^b   Suzuki, Tsutomu ^a  

^a HOSHI UNIVERSITY   (Japan)

^b JOSAI INTERNATIONAL UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALOXONE; FENTANYL; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALOXONAZINE; OXYCODONE;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; GASTROINTESTINAL TRANSIT; IN VITRO STUDY; INTESTINE FUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANALGESICS, OPIOID; ANIMALS; CONSTIPATION; GASTROINTESTINAL TRANSIT; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MICE, INBRED ICR; NARCOTIC ANTAGONISTS; ORGAN CULTURE TECHNIQUES; RECEPTORS, OPIOID, MU;

EID: 84884610342     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.204313     Document Type: Article

References (35)

1. Ackerman SJ, Knight T, Schein J, Carter C, and Staats P (2004) Risk of constipation in patients prescribed fentanyl transdermal system or oxycodone hydrochloride controlled-release in a California Medicaid population. Consult Pharm 19:118-132.
2. Becker G and Blum HE (2009) Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet 373:1198-1206.
3. Baker AK and Meert TF (2002) Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice. J Pharmacol Exp Ther 302:1253-1264.
4. Boström E, Hammarlund-Udenaes M, and Simonsson US (2008) Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology 108:495-505.
5. Cadet P (2004) Mu opiate receptor subtypes. Med Sci Monit 10:MS28-MS32.
6. Dagenais C, Graff CL, and Pollack GM (2004) Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67:269-276.
7. Elliott J, Smart D, Lambert DG, and Traynor JR (1994) Characterisation of muopioid receptors on SH-SY5Y cells using naloxonazine and beta-funaltrexamine. Eur J Pharmacol 268:447-450.
8. Finkel JC, Pestieau SR, and Quezado ZM (2007) Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain 8:515-521.
9. Gmerek DE, Cowan A, and Woods JH (1986) Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J Pharmacol Exp Ther 236:8-13.
10. Greenwood-Van Meerveld B and Standifer KM (2008) Methylnaltrexone in the treatment of opioid-induced constipation. Clin Exp Gastroenterol 1:49-58.
11. Haley TJ (1957) 5-Hydroxytryptamine antagonism by lysergic acid diethylamide after intracerebral injection in conscious mice. J Am Pharm Assoc Am Pharm Assoc (Baltim) 46:428-430.
12. Heyman JS, Williams CL, Burks TF, Mosberg HI, and Porreca F (1988) Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. J Pharmacol Exp Ther 245:238-243.
13. Holzer P, Ahmedzai SH, Niederle N, Leyendecker P, Hopp M, Bosse B, Spohr I, and Reimer K (2009) Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag 5:145-151.
14. Hylden JL and Wilcox GL (1980) Intrathecal morphine in mice: a new technique. Eur J Pharmacol 67:313-316.
15. Kang M, Maguma HT, Smith TH, Ross GR, Dewey WL, and Akbarali HI (2012) The role of b-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract. J Pharmacol Exp Ther 340:567-576.
16. Koslo RJ, Burks TF, and Porreca F (1986) Centrally administered bombesin affects gastrointestinal transit and colonic bead expulsion through supraspinal mechanisms. J Pharmacol Exp Ther 238:62-67.
17. Leppert W (2010) The role of opioid receptor antagonists in the treatment of opioidinduced constipation: a review. Adv Ther 27:714-730.
18. Matsuzawa S, Suzuki T, and Misawa M (2000) Involvement of mu-opioid receptor in the salsolinol-associated place preference in rats exposed to conditioned fear stress. Alcohol Clin Exp Res 24:366-372.
19. Minami K, Hasegawa M, Ito H, Nakamura A, Tomii T, Matsumoto M, Orita S, Matsushima S, Miyoshi T, and Masuno K, et al. (2009) Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci 111:60-72.
20. Nakamura A, Hasegawa M, Ito H, Minami K, Koike K, Habu-Tomita N, Nanba K, Hamaguchi K, Noshi E, and Hashimoto H, et al. (2011) Distinct relations among plasma concentrations required for different pharmacological effects in oxycodone, morphine, and fentanyl. J Pain Palliat Care Pharmacother 25:318-334.
21. Narita M, Kishimoto Y, Ise Y, Yajima Y, Misawa K, and Suzuki T (2005) Direct evidence for the involvement of the mesolimbic kappa-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state. Neuropsychopharmacology 30:111-118.
22. Pasternak GW (1993) Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 16:1-18.
23. Pol O, Valle L, Sánchez-Blázquez P, Garzón J, and Puig MM (1999) Antibodies and antisense oligodeoxynucleotides to mu-opioid receptors, selectively block the effects of mu-opioid agonists on intestinal transit and permeability in mice. Br J Pharmacol 127:397-404.
24. Radbruch L and Elsner F (2004) Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany. Keio J Med 53:23-29.
25. Raffa RB, Mathiasen JR, and Jacoby HI (1987) Colonic bead expulsion time in normal and mu-opioid receptor deficient (CXBK) mice following central (ICV) administration of mu- and delta-opioid agonists. Life Sci 41:2229-2234.
26. Ross GR, Gabra BH, Dewey WL, and Akbarali HI (2008) Morphine tolerance in the mouse ileum and colon. J Pharmacol Exp Ther 327:561-572.
27. Shook JE, Pelton JT, Hruby VJ, and Burks TF (1987) Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther 243:492-500.
28. Suzuki T, Mori T, Tsuji M, Misawa M, and Nagase H (1995) Discriminative stimulus properties of morphine mediated by mu 1-opioid receptors. Eur J Pharmacol 284: 195-198.
29. Swegle JM and Logemann C (2006) Management of common opioid-induced adverse effects. Am Fam Physician 74:1347-1354.
30. Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB, and Israel RJ (2008) Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 358:2332-2343.
31. Torigoe K, Nakahara K, Rahmadi M, Yoshizawa K, Horiuchi H, Hirayama S, Imai S, Kuzumaki N, Itoh T, and Yamashita A, et al. (2012) Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain. Anesthesiology 116:159-169.
32. WHO (1996) Cancer Pain Relief, World Health Organization, Geneva.
33. Weschules DJ, Bain KT, Reifsnyder J, McMath JA, Kupperman DE, Gallagher RM, Hauck WW, and Knowlton CH (2006) Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients. Pain Med 7:320-329.
34. Yamada K and Onoda Y (1992) Effects of trimebutine on colonic propulsion in mice. J Smooth Muscle Res 28:87-93.
35. Yu Y, Cui Y, Wang X, Lai LH, Wang CL, Fan YZ, Liu J, and Wang R (2007) In vitro characterization of the effects of endomorphin 1 and 2, endogenous ligands for muopioid receptors, on mouse colonic motility. Biochem Pharmacol 73:1384-1393.